Robert L. McNamara, MD, MHS; Leonardo J. Tamariz, MD, MPH; Jodi B. Segal, MD, MPH; Eric B. Bass, MD, MPH
Disclaimer: The authors are responsible for the content of this article, including any treatment recommendations. No statement in this article should be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.
Acknowledgments: The authors thank Karen Robinson and Drs. Marlene Miller, Steve Goodman, and Neil Powe for their valuable contribution to the Evidence-based Report on the Management of Atrial Fibrillation.
Grant Support: Portions of this background paper were drawn from a review conducted by the Johns Hopkins Evidence-based Practice Center through Contract No. 290-97-0006 from the Agency for Healthcare Research and Quality, Rockville, MD. Dr. Tamariz was supported by a training grant in behavioral research in heart and vascular diseases from the National Heart, Lung, and Blood Institute (T32HL07180).
Potential Financial Conflicts of Interest:Consultancies: R.L. McNamara (Aventis, EU3); Grants received: L.J. Tamariz (National Heart, Lung, and Blood Institute).
Requests for Single Reprints: Robert L. McNamara, MD, MHS, Cardiovascular Section, Yale University, 333 Cedar Street, 316 FMP, P.O. Box 208017, New Haven, CT 06520-8017; e-mail, firstname.lastname@example.org.
Current Author Addresses: Dr. McNamara: Cardiovascular Section, Yale University, 333 Cedar Street, 315A FMP, P.O. Box 208017, New Haven, CT 06520-8017.
Dr. Tamariz: 2024 East Monument Street, Room 2-516, Baltimore, MD 21205.
Dr. Segal: 720 Rutland Avenue, Ross #1025, Baltimore, MD 21205.
Dr. Bass: 1830 East Monument Street, Room 8068, Baltimore, MD 21287.
This review summarizes the available evidence regarding the efficacy of medications used for ventricular rate control, stroke prevention, acute conversion, and maintenance of sinus rhythm, as well as the efficacy of electrical cardioversion and the use of echocardiography in patients with atrial fibrillation.
The Cochrane Collaboration's database of controlled clinical trials and MEDLINE.
Primarily randomized, controlled trials of medications.
Paired reviewers obtained data on efficacy and safety. Strength of evidence was assessed.
Recent clinical trial results showed that most patients with atrial fibrillation have similar outcomes with strategies for controlling ventricular rate compared with strategies for restoring sinus rhythm. For efficacy of primary stroke prevention, compared with placebo, evidence was strong for warfarin and suggestive for aspirin. The evidence for an increased risk for major bleeding was suggestive for warfarin and inconclusive for aspirin. For ventricular rate control, verapamil, diltiazem, atenolol, and metoprolol were qualitatively superior to digoxin and placebo, particularly during exercise. For efficacy of acute conversion, compared with placebo, evidence was strong for ibutilide, flecainide, dofetilide, propafenone, amiodarone, and quinidine. For efficacy of maintenance of sinus rhythm after conversion from atrial fibrillation, evidence was strong for amiodarone, propafenone, disopyramide, and sotalol. Echocardiography was found to be useful in estimating risk for thromboembolism and potentially useful in estimating likelihood of successful cardioversion and maintenance.
For several key questions in the pharmacologic management of atrial fibrillation, strong evidence exists to support 1 or more treatment options.
Absolute rates of stroke and hemorrhage for trials comparing warfarin or aspirin with control.
Table 1. Meta-Analysis of Primary Prevention of Stroke in Atrial Fibrillation
Proportions of patients who had successful pharmacologic intervention.
Table 2. Pooled Results for the Efficacy and Adverse Effects of Drugs Used in Acute Conversion of Atrial Fibrillation
Table 3. Pooled Results of Randomized, Controlled Trials of Drugs for Maintenance of Sinus Rhythm after Conversion of Atrial Fibrillation
Proportions of patients who had successful maintenance of sinus rhythm.
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
McNamara RL, Tamariz LJ, Segal JB, Bass EB. Management of Atrial Fibrillation: Review of the Evidence for the Role of Pharmacologic Therapy, Electrical Cardioversion, and Echocardiography. Ann Intern Med. ;139:1018–1033. doi: 10.7326/0003-4819-139-12-200312160-00012
Download citation file:
Published: Ann Intern Med. 2003;139(12):1018-1033.
Cardiology, Guidelines, Rhythm Disorders and Devices.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use